Given that immunoproteasome inhibitors are currently being developed for a variety of
potent therapeutic purposes, the unique specificity of an α′, β′-epoxyketone peptide …

Immunoproteasomes contain replacements for the three catalytic subunits of standard
proteasomes. In most cells, oxidative stress and proinflammatory cytokines are stimuli that …

The immunoproteasome is expressed in cells of hematopoietic origin and is induced during
inflammation by IFN-γ. Targeting the immunoproteasome with selective inhibitors has been …

The assembly of eukaryotic 20 S proteasomes involves the formation of half-proteasomes
where precursor β-type subunits gather in position on an α-subunit ring, followed by the …

The proteasome is the main provider of peptide ligands for major histocompatibility complex
class I molecules. During an immune response to pathogens, the proinflammatory cytokine …

The concept of proteasome inhibition ranks among the latest achievements in the treatment
of blood cancer and represents a promising strategy for modulating autoimmune diseases …

The proteasome is responsible for the generation of most epitopes presented on MHC class
I molecules. Treatment of cells with IFN-γ leads to the replacement of the constitutive …

The proteasome is a multicatalytic protease complex that mediates the controlled
degradation of intracellular proteins, including key components of pathways that contribute …

Selective inhibition of the immunoproteasome is a promising approach towards the
development of immunomodulatory drugs. Recently, a class of substituted thiazole …

The mammalian 26S proteasome is a 2500 kDa multi-catalytic complex involved in
intracellular protein degradation. We describe the synthesis and properties of a novel series …